Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Connolly, Stuart J., Ezekowitz, Michael D., Yusuf, Salim, Eikelboom, John, Oldgren, Jonas, Parekh, Amit, Pogue, Janice, Reilly, Paul A., Themeles, Ellison, Varrone, Jeanne, Wang, Susan, Alings, Marco, Xavier, Denis, Zhu, Jun, Diaz, Rafael, Lewis, Basil S., Darius, Harald, Diener, Hans-Christoph, Joyner, Campbell D., Wallentin, Lars·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0905561

Cited by (1,022)

Items 101–200 of 1,022

  1. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary
    Bernard John Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski et al. · 2011 · Circulation
  2. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
    Heidbuchel, Hein, Verhamme, Peter, Alings, Marco, Antz, Matthias, Hacke, Werner, Oldgren, Jonas, Sinnaeve, Peter, Camm, A. John, Kirchhof, Paulus · 2013 · Europace
  3. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension.
    2019 · PubMed Central
  4. Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
    Larry B. Goldstein, Cheryl Bushnell, Robert J. Adams, Lawrence J. Appel, Lynne T. Braun, Seemant Chaturvedi, Mark A. Creager, Antonio Culebras, Robert H. Eckel, Robert G. Hart et al. · 2011 · Stroke
  5. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage
    Jennifer Ann Frontera, John J. Lewin, Alejandro A. Rabinstein, Imoigele P. Aisiku, Anne W. Alexandrov, Aaron M. Cook, Gregory J. del Zoppo, Monisha A. Kumar, Ellinor I.B. Peerschke, Michael Stiefel et al. · 2015 · Neurocritical Care
  6. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease
    Khairy, Paul, Van Hare, George F., Balaji, Seshadri, Berul, Charles I., Cecchin, Frank, Cohen, Mitchell I., Daniels, Curt J., Deal, Barbara J., Dearani, Joseph A., Groot, Natasja de et al. · 2014 · Heart Rhythm
  7. Newly identified events in the RE-LY trial
    Connolly, Stuart J., Ezekowitz, Michael D., Yusuf, Salim, Reilly, Paul A., Wallentin, Lars · 2010 · New England Journal of Medicine
  8. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation
    Vivek Yerrapu Reddy, Shephal K. Doshi, Horst Sievert, Maurice Buchbinder, Petr Neužil, Kenneth Huber, Jonathan L. Halperin, David R. Holmes · 2013 · Circulation
  9. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
    Ashley Chen, Eric C. Stecker, Bruce A. Warden · 2020 · Journal of the American Heart Association
  10. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
    Demaerschalk, Bart M., Kleindorfer, Dawn O., Adeoye, Opeolu M., Demchuk, Andrew M., Fugate, Jennifer E., Grotta, James C., Khalessi, Alexander A., Levy, Elad I., Palesch, Yuko Y., Prabhakaran, Shyam et al. · 2016 · Stroke
  11. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
    Stylianos E. Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, Eduardo Saad, Alireza Sepehri Shamloo, Jason G. Andrade, Chirag R. Barbhaiya, Tina Baykaner, Serge Bovéda, Hugh G Calkins et al. · 2024 · EP Europace
  12. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation
    Pavel P. Osmancik, Dalibor Heřman, Petr Neužil, Pavel Hála, Miloš Táborský, Petr Kala, Martin Poloczek, Josef Šťásek, Luděk Haman, Marian Branny et al. · 2020 · Journal of the American College of Cardiology
  13. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation
    Graham, David J., Reichman, Marsha E., Wernecke, Michael, Zhang, Rongmei, Southworth, Mary Ross, Levenson, Mark, Sheu, Ting-Chang, Mott, Katrina, Goulding, Margie R., Houstoun, Monika et al. · 2015 · Circulation
  14. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
    Julie A. Johnson, Li Gong, Michelle Whirl‐Carrillo, Brian F. Gage, Stuart Alexander Scott, C. Michael Stein, Jeffrey L. Anderson, Stephen E. Kimmel, M T M Lee, Munir Pirmohamed et al. · 2011 · Clinical Pharmacology & Therapeutics
  15. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century
    Jocasta Ball, Melinda Jane Carrington, John J.V. McMurray, Simon Stewart · 2013 · International Journal of Cardiology
  16. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R. et al. · 2011 · European Heart Journal
  17. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
    Lars Rydén, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino, Nicolas Danchin, Christi Deaton, Javier Escaned, Hans‐Peter Hammes, Heikki Huikuri et al. · 2014 · Revista Española de Cardiología (English Edition)
  18. National trends in ambulatory oral anticoagulant use
    Barnes, Geoffrey D., Lucas, Eleanor, Alexander, G. Caleb, Goldberger, Zachary D. · 2015 · The American Journal of Medicine
  19. Cross Talk Pathways Between Coagulation and Inflammation
    Jonathan H. Foley, Edward M. Conway · 2016 · Circulation Research
  20. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
    Shunichi Homma, John L.P. Thompson, Patrick M. Pullicino, Bruce Lubotsky Levin, Ronald S. Freudenberger, John R. Teerlink, Susan E. Ammon, Susan Graham, Ralph L. Sacco, Douglas L. Mann et al. · 2012 · New England Journal of Medicine
  21. Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation
    David H. Birnie, Jeff S. Healey, George A. Wells, Atul Verma, ANTHONY S.L. TANG, Andrew David Krahn, Christopher S. Simpson, Felix Ayala Paredes, Benoit Coutu, Tiago Luiz Luz Leiria et al. · 2013 · New England Journal of Medicine
  22. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
    Craig T. January, L. Samüel Wann, Joseph S. Alpert, Hugh G Calkins, Joaquin E. Cigarroa, Joseph C. Cleveland, JAMIE BETH CONTI, Patrick T. Ellinor, Michael D. Ezekowitz, Michael E. Field et al. · 2014 · Journal of the American College of Cardiology
  23. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage
    Kuramatsu, Joji B., Gerner, Stefan T., Schellinger, Peter D., Glahn, Jörg, Endres, Matthias, Sobesky, Jan, Flechsenhar, Julia, Neugebauer, Hermann, Jüttler, Eric, Grau, Armin et al. · 2015 · JAMA
  24. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)
    Task Force Members, Gregory Y.H. Lip, Stephan Windecker, Kurt Huber, Paulus F. Kirchhof, Francisco R. Marín, Jurriën M. ten Berg, Karl Georg Hæusler, Giuseppe Boriani, Davide Capodanno et al. · 2014 · European Heart Journal
  25. The Hemostatic System as a Modulator of Atherosclerosis
    Julian Ilcheff Borissoff, Henri M.H. Spronk, Hugo Ten Cate · 2011 · New England Journal of Medicine
  26. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation
    Jason G. Andrade, Martín Aguilar, Clare L. Atzema, Alan Bell, John A. Cairns, Christopher C. Cheung, Jafna L. Cox, Paul Dorian, David J. Gladstone, Jeff S. Healey et al. · 2020 · Canadian Journal of Cardiology
  27. A specific antidote for dabigatran: functional and structural characterization
    Felix Schiele, Joanne van Ryn, Keith A. Canada, Corey Newsome, Eliud Sepulveda, John Park, Herbert Nar, Tobias Litzenburger · 2013 · Blood
  28. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
    José A López-López, Jonathan A C Sterne, Howard H. Z. Thom, Julian P. T. Higgins, Aroon Dinesh Hingorani, George N. Okoli, Philippa A. Davies, Pritesh N. Bodalia, Peter A. Bryden, Nicky J. Welton et al. · 2017 · BMJ
  29. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
    Frank L.J. Visseren, François Mach, Yvo Michiel Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Bénétos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno et al. · 2021 · European Journal of Preventive Cardiology
  30. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation
    Holmes, David R., Doshi, Shephal K., Kar, Saibal, Price, Matthew J., Sanchez, Jose M., Sievert, Horst, Valderrabano, Miguel, Reddy, Vivek Y. · 2015 · Journal of the American College of Cardiology
  31. The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation
    Juan F. Viles-González, Saibal Kar, Pamela S. Douglas, Srinivas Rao Dukkipati, Ted E Feldman, Rodney Horton, David R. Holmes, Vivek Yerrapu Reddy · 2012 · Journal of the American College of Cardiology
  32. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
    Jeff S. Healey, John W. Eikelboom, James Demetrios Douketis, Lars C. Wallentin, Jonas Oldgren, Sean Yang, Ellison Themeles, Hein Heidbüchel, Álvaro Avezum, Paul A. Reilly et al. · 2012 · Circulation
  33. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
    Raphaël Marlu, Enkelejda Hodaj, Adeline Paris, Pierre Albaladejo, Jean‐Luc Cracowski, Gilles Pernod · 2012 · Thrombosis and Haemostasis
  34. Biochemistry and biology of mammalian DNA methyltransferases
    A. Hermann, Humaira Gowher, Albert Jeltsch · 2004 · Cellular and Molecular Life Sciences
  35. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    Jonas Oldgren, Andrzej Budaj, Christopher Bull Granger, Yasser Khder, J. Roberts, Agneta Siegbahn, Jan G.P. Tijssen, Frans Van de Werf, Lars C. Wallentin, for the RE-DEEM Investigators · 2011 · European Heart Journal
  36. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation
    Rangadham Nagarakanti, Michael D. Ezekowitz, Jonas Oldgren, Sean Yang, Michael Ross Chernick, Timothy H. Aikens, Greg Flaker, Josép Brugada, Gabriel Kamenský, Amit Parekh et al. · 2011 · Circulation
  37. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control
    Allan Cameron Skanes, Jeff S. Healey, John A. Cairns, Paul Dorian, Anne M. Gillis, Michael Sean McMurtry, L. Brent Mitchell, Atul Verma, Stanley Nattel · 2012 · Canadian Journal of Cardiology
  38. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States
    Konstantinos C. Siontis, Xiaosong Zhang, Ashley Eckard, Nicole Martin Bhave, Douglas Earl Schaubel, Kevin He, Anca M. Tilea, Austin G. Stack, Rajesh Balkrishnan, Xiaoxi Yao et al. · 2018 · Circulation
  39. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes
    Benjamin Adam Steinberg, Peter Shrader, Laine Elliott Thomas, Jack Ansell, Gregg C. Fonarow, Bernard John Gersh, Peter Russell Kowey, Kenneth W. Mahaffey, Gerald V. Naccarelli, James A. Reiffel et al. · 2016 · Journal of the American College of Cardiology
  40. Identifying Patients at High Risk for Stroke Despite Anticoagulation
    Gregory Y.H. Lip, Lars Frison, Jonathan L. Halperin, Deirdre A. Lane · 2010 · Stroke
  41. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
    Hijazi, Ziad, Oldgren, Jonas, Lindbäck, Johan, Alexander, John H, Connolly, Stuart J, Eikelboom, John W, Ezekowitz, Michael D, Held, Claes, Hylek, Elaine M, Lopes, Renato D et al. · 2016 · The Lancet
  42. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    Dans, Antonio L., Connolly, Stuart J., Wallentin, Lars, Yang, Sean, Nakamya, Juliet, Brueckmann, Martina, Ezekowitz, Michael, Oldgren, Jonas, Eikelboom, John W., Reilly, Paul A. et al. · 2013 · Circulation
  43. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
    Christian Thomas Ruff, Robert Patrick Giugliano, Elliott Marshall Antman, Sharon E. Crugnale, Tomás S. Bocanegra, Michele F. Mercuri, JAMES J. HANYOK, Indravadan J. Patel, Minggao Shi, Dan Salazar et al. · 2010 · American Heart Journal
  44. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Atul Verma, John A. Cairns, L. Brent Mitchell, Laurent Macle, Ian Gilmour Stiell, David J. Gladstone, Michael Sean McMurtry, Stuart J. Connolly, Jafna L. Cox, Paul Dorian et al. · 2014 · Canadian Journal of Cardiology
  45. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
    Tze‐Fan Chao, Boyoung Joung, Yoshihide Takahashi, Toon Wei Lim, Eue‐Keun Choi, Yi‐Hsin Chan, Yutao Guo, Charn Sriratanasathavorn, Seil Oh, Ken Okumura et al. · 2021 · Thrombosis and Haemostasis
  46. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: The SEARCH-AF study
    Lowres, Nicole, Neubeck, Lis, Salkeld, Glenn, Krass, Ines, McLachlan, Andrew J., Redfern, Julie, Bennett, Alexandra A., Briffa, Tom, Bauman, Adrian, Martinez, Carlos et al. · 2014 · Thrombosis and Haemostasis
  47. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
    Xiaoxi Yao, Nilay D. Shah, Lindsey R. Sangaralingham, Bernard John Gersh, Peter A. Noseworthy · 2017 · Journal of the American College of Cardiology
  48. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment
    Kazuma Fujimoto, Mitsuhiro Fujishiro, Mototsugu Kato, Kazuhide Higuchi, Ryuichi Iwakiri, Choitsu Sakamoto, Shinichiro Uchiyama, Atsunori Kashiwagi, Hisao Ogawa, Kazunari Murakami et al. · 2013 · Digestive Endoscopy
  49. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
    Renato D. Lópes, John Hunter Alexander, Sana M. Al‐Khatib, Jack Ansell, Raphael Diaz, J. Donald Easton, Bernard John Gersh, Christopher Bull Granger, Michael Hanna, John David Horowitz et al. · 2010 · American Heart Journal
  50. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study
    Friberg, Leif, Rosenqvist, Mårten, Lip, Gregory Y.H. · 2012 · Circulation
  51. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
    Diener, Hans-Christoph, Connolly, Stuart J, Ezekowitz, Michael D, Wallentin, Lars, Reilly, Paul A, Yang, Sean, Xavier, Denis, Di Pasquale, Giuseppe, Yusuf, Salim · 2010 · The Lancet Neurology
  52. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
    A. John Camm, Pierre Amarenco, Sylvia K. Haas, Susanne Hess, Paulus F. Kirchhof, Silvia Kuhls, Martin van Eickels, Alexander G.G. Turpie · 2015 · European Heart Journal
  53. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
    Xiaoxi Yao, Neena S. Abraham, G. Caleb Alexander, William H. Crown, Víctor M. Montori, Lindsey R. Sangaralingham, Bernard John Gersh, Nilay D. Shah, Peter A. Noseworthy · 2016 · Journal of the American Heart Association
  54. Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
    Adam C. Cuker, Deborah M. Siegal, Mark Andrew Crowther, David A. Garcia · 2014 · Journal of the American College of Cardiology
  55. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
    Karlyn A. Martin, Jan Beyer‐Westendorf, Bruce L. Davidson, Menno Volkert Huisman, Per Morten Sandset, Stephan Moll · 2016 · Journal of Thrombosis and Haemostasis
  56. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
    Ajay K. Kakkar, Iris Mueller, Jean‐Pierre Bassand, David Andrew Fitzmaurice, Samuel Zachary Goldhaber, Shinya Goto, Sylvia K. Haas, Werner Hacke, Gregory Y.H. Lip, Lorenzo Giovanni Mantovani et al. · 2013 · PLoS ONE
  57. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
    Piotr P. Ponikowski, Adriaan A. Voors, Stefan D. Anker, Héctor Bueno, John G.F. Cleland, Andrew J.S. Coats, Volkmar Falk, José Ramón González‐Juanatey, Veli‐Pekka Harjola, Ewa Anita Jankowska et al. · 2016 · Kardiologia Polska
  58. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation
    John U. Doherty, Ty J. Gluckman, William J. Hucker, James L. Januzzi, Thomas L. Ortel, Sherry J. Saxonhouse, Sarah A. Spinler · 2017 · Journal of the American College of Cardiology
  59. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
    Torben Bjerregaard Larsen, Flemming Skjøth, Peter Brønnum Nielsen, Jette Nordstrøm Kjældgaard, Gregory Y.H. Lip · 2016 · BMJ
  60. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
    Hugh G Calkins, Stephan Willems, Edward P. Gerstenfeld, Atul Verma, RICHARD JOHN SCHILLING, Stefan Hans Hohnloser, Ken Okumura, Harvey Serota, Matias Nordaby, Kelly Guiver et al. · 2017 · New England Journal of Medicine
  61. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation
    Corey Miller, Sonia Marzia Grandi, Avi Shimony, Kristian B. Filion, Mark Jeffrey Eisenberg · 2012 · The American Journal of Cardiology
  62. Cardioembolic Stroke
    Hooman Kamel, Jeff S. Healey · 2017 · Circulation Research
  63. Dabigatran Association With Higher Risk of Acute Coronary Events
    Ken Uchino · 2012 · Archives of Internal Medicine
  64. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study
    Lip, Gregory, Lindhardsen, Jesper, Lane, Deirdre, Ahlehoff, Ole, Hansen, Morten, Raunsø, Jakob, Tolstrup, Janne, Hansen, Peter, Gislason, Gunnar, Torp-Pedersen, Christian et al. · 2011 · Thrombosis and Haemostasis
  65. Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    James V. Freeman, Ruo P. Zhu, Douglas K Owens, Alan M. Garber, David W. Hutton, Alan S. Go, Paul J. Wang, Mintu P. Turakhia · 2011 · Annals of Internal Medicine
  66. Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experience
    Jai‐Wun Park, Armando Bethencourt, Horst Sievert, Gennaro Santoro, Bernhard Meier, Kevin Patrick Walsh, Jose Ramon Lopez-Minquez, David Meerkin, Mariano Valdés, Oliver J. Ormerod et al. · 2010 · Catheterization and Cardiovascular Interventions
  67. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Xiaoxi Yao, Neena S. Abraham, Lindsey R. Sangaralingham, Fernanda Bellolio, Robert D. McBane, Nilay D. Shah, Peter A. Noseworthy · 2016 · Journal of the American Heart Association
  68. The NCDR Left Atrial Appendage Occlusion Registry
    James V. Freeman, Paul D. Varosy, Matthew J. Price, David J. Slotwiner, Fred M Kusumoto, Chidambaram Rammohan, Clifford J. Kavinsky, Zoltan G. Turi, Joseph G. Akar, Cristina Koutras et al. · 2020 · Journal of the American College of Cardiology
  69. Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation
    Krzysztof Bartuś, Frederick T. Han, Jacek Bednarek, Jacek Myć, Bogusław Kapelak, Jerzy Sadowski, Jacek Lelakowski, Stanisław Bartuś, Steven Joseph Yakubov, Randall J. Lee · 2012 · Journal of the American College of Cardiology
  70. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
    Marco Valgimigli, Héctor Bueno, Robert A. Byrne, Jean‐Philippe Collet, Francesco Costa, Anders Jeppsson, Peter Jüni, Adnan Kastrati, Philippe H. Kolh, Laura Mauri et al. · 2017 · European Journal of Cardio-Thoracic Surgery
  71. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
    Agon Mekaj, Ymer Mekaj, Shkelzen B. Duci, Ermira Miftari · 2015 · Therapeutics and Clinical Risk Management
  72. New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
    Ingrid Lisanne Holster, Vera E. Valkhoff, Ernst Johan Kuipers, Eric T.T.L. Tjwa · 2013 · Gastroenterology
  73. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
    Ruff, Christian T, Giugliano, Robert P, Braunwald, Eugene, Morrow, David A, Murphy, Sabina A, Kuder, Julia F, Deenadayalu, Naveen, Jarolim, Petr, Betcher, Joshua, Shi, Minggao et al. · 2015 · The Lancet
  74. Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran
    Robert G. Hart, Hans‐Christoph Diener, Sean Yang, Stuart J. Connolly, Lars C. Wallentin, Paul A. Reilly, Michael D. Ezekowitz, Salim Yusuf · 2012 · Stroke
  75. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
    Hein Heidbüchel, Peter B. Verhamme, Marco Alings, Matthias Antz, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A. John Camm, Paulus F. Kirchhof · 2013 · European Heart Journal
  76. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation
    Craig T. January, L. Samüel Wann, Hugh G Calkins, Lin Y. Chen, Joaquin E. Cigarroa, Joseph C. Cleveland, Patrick T. Ellinor, Michael D. Ezekowitz, Michael E. Field, Karen L. Furie et al. · 2019 · Heart Rhythm
  77. Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation
    Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, Flemming Skjøth, Karen Margrete Due, Torbjörn Callréus, Mary Rosenzweig, Gregory Y.H. Lip · 2013 · Journal of the American College of Cardiology
  78. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)
    Ola Einar Dahl, Michael H. Huo, Andreas Alois Kurth, Stefan Hantel, Karin Hermansson, Janet M. Schnee, Richard Joel Friedman, Bengt I. Eriksson, for the RE-NOVATE II Study Group · 2011 · Thrombosis and Haemostasis
  79. Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy
    Hijazi, Ziad, Oldgren, Jonas, Andersson, Ulrika, Connolly, Stuart J., Ezekowitz, Michael D., Hohnloser, Stefan H., Reilly, Paul A., Vinereanu, Dragos, Siegbahn, Agneta, Yusuf, Salim et al. · 2012 · Circulation
  80. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)
    L. Samüel Wann, Anne B. Curtis, Kenneth A. Ellenbogen, N.A. Mark Estes, Michael D. Ezekowitz, Warren M. Jackman, Craig T. January, James E. Lowe, Richard L. Page, David J. Slotwiner et al. · 2011 · Circulation
  81. Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment (FAST): A 2-Center Randomized Clinical Trial
    Boersma, Lucas V.A., Castella, Manuel, van Boven, WimJan, Berruezo, Antonio, Yilmaz, Alaaddin, Nadal, Mercedes, Sandoval, Elena, Calvo, Naiara, Brugada, Josep, Kelder, Johannes et al. · 2012 · Circulation
  82. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
    Hijazi, Ziad, Hohnloser, Stefan H., Oldgren, Jonas, Andersson, Ulrika, Connolly, Stuart J., Eikelboom, John W., Ezekowitz, Michael D., Reilly, Paul A., Siegbahn, Agneta, Yusuf, Salim et al. · 2014 · Circulation
  83. Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
    Shang‐Hung Chang, I‐Jun Chou, Yung‐Hsin Yeh, Meng‐Jiun Chiou, Ming‐Shien Wen, Chi-Tai Kuo, Lai‐Chu See, Chang‐Fu Kuo · 2017 · JAMA
  84. 2020 Clinical practice guidelines for Chronic heart failure
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
  85. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)
    L. Samüel Wann, Anne B. Curtis, Kenneth A. Ellenbogen, N.A. Mark Estes, Michael D. Ezekowitz, Warren M. Jackman, Craig T. January, James E. Lowe, Richard L. Page, David J. Slotwiner et al. · 2011 · Heart Rhythm
  86. Challenges in the design and interpretation of Noninferiority trials
    Mauri, Laura, D’Agostino, Ralph B. · 2017 · New England Journal of Medicine
  87. Therapeutic strategies for thrombosis: new targets and approaches
    Nigel Mackman, Wolfgang Bergmeier, George A. Stouffer, Jeffrey Ian Weitz · 2020 · Nature Reviews Drug Discovery
  88. Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease
    Therese M. Giglia, Mary Patricia Massicotte, James S. Tweddell, Robyn J. Barst, Mary Elisabeth Bauman, Christopher C. Erickson, Timothy F. Feltes, Elyse Foster, Kathleen Hinoki, Rebecca Ichord et al. · 2013 · Circulation
  89. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions
    Charidimou, Andreas, Linn, Jennifer, Vernooij, Meike W., Opherk, Christian, Akoudad, Saloua, Baron, Jean-Claude, Greenberg, Steven M., Jäger, Hans Rolf, Werring, David J. · 2015 · Brain
  90. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
    Anthony Carnicelli, Hwanhee Hong, Stuart J. Connolly, John W. Eikelboom, Robert Patrick Giugliano, David A. Morrow, Manesh R. Patel, Lars C. Wallentin, John Hunter Alexander, Maria Cecilia Bahit et al. · 2022 · Circulation
  91. Cardiovascular effects and safety of (non-aspirin) NSAIDs
    Schjerning, Anne-Marie, McGettigan, Patricia, Gislason, Gunnar · 2020 · Nature Reviews Cardiology
  92. Insights Into Onco-Cardiology
    Dimitrios T. Farmakis, John Parissis, Gerasimos S Filippatos · 2013 · Journal of the American College of Cardiology
  93. Secondary stroke prevention
    Graeme J. Hankey · 2013 · The Lancet Neurology
  94. Deep vein thrombosis: pathogenesis, diagnosis, and medical management
    Jonathan J. Stone, Patrick T. Hangge, Hassan Albadawi, Alex Wallace, Fadi Elias Shamoun, M. Grace Knuttinen, Sailendra Naidu, Rahmi Öklü · 2017 · Cardiovascular Diagnosis and Therapy
  95. Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation
    Francesco Dentali, Nicoletta Riva, Mark Andrew Crowther, Alexander G.G. Turpie, Gregory Y.H. Lip, Walter Ageno · 2012 · Circulation
  96. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry
    Jan Beyer‐Westendorf, Vera Gelbricht, K. Förster, Franziska Ebertz, Christina U. Köhler, Sebastian Werth, Eberhard Kuhlisch, Thoralf Stange, C. Thieme, Katharina Daschkow et al. · 2014 · European Heart Journal
  97. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
    Thorsten Steiner, Sven Poli, Martin Griebe, Johannes Hüsing, Jacek Hajda, Anja Freiberger, Martin Bendszus, Julian Bösel, Hanne Christensen, Christian Dohmen et al. · 2016 · The Lancet Neurology
  98. The Global Burden of Atrial Fibrillation and Stroke
    Gregory Y.H. Lip, Carolyn M. Brechin, Deirdre A. Lane · 2012 · CHEST Journal
  99. How I treat anticoagulated patients undergoing an elective procedure or surgery
    Alex C. Spyropoulos, James Demetrios Douketis · 2012 · Blood
  100. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
    Riccardo Cappato, Michael D. Ezekowitz, Allan L. Klein, A. John Camm, Changsheng Ma, Jean‐Yves Le Heuzey, Mario R. Talajic, Maurício Scanavacca, Panos E. Vardas, Paulus F. Kirchhof et al. · 2014 · European Heart Journal